Who are Lakefront Biotherapeutics NV's major customers?

Lakefront Biotherapeutics NV (GLPG) key customers include: Gilead Sciences, Inc., Gilead Sciences, Inc., CHARLES-RIVER-LABORATORIES-HOLDING-LIMITED, Charles River Laboratories International, Inc., GALAPAGOS-GMBH and 7 more. View the full customer network at chainsifter.com/chain/GLPG.

What sector is Lakefront Biotherapeutics NV in?

Lakefront Biotherapeutics NV (GLPG) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Lakefront Biotherapeutics NV (GLPG) Suppliers & Customers

0Suppliers

12Customers

1Debt Items

20Related Chains

Source-Backed Evidence Depth

Lakefront Biotherapeutics NV (GLPG) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

14Total relationships

1Distinct source URLs

2High confidence

0.674Average confidence

2026-09-14Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Lakefront Biotherapeutics NV Suppliers

No suppliers on recordLakefront Biotherapeutics NV has not yet been matched to upstream suppliers in our database, or is still being processed.

Lakefront Biotherapeutics NV Customers

Ticker	Name	Confidence	Evidence
GILD	Gilead Sciences, Inc.	72%	24: € 49.5 thousand) related to tax assistance. The Audit Committee and the Board of Directors are of the opinion that these non-audit services do not affect the independence of the statutory auditor…
GILD	Gilead Sciences, Inc.	72%	Reciprocal relationship from GILD graph: Reciprocal relationship from GLPG graph: 24: € 49.5 thousand) related to tax assistance. The Audit Committee and the Board of Directors are of the opinion tha…
CHARLES-RIVER-LABORATORIES-HOLDING-LIMITED	CHARLES-RIVER-LABORATORIES-HOLDING-LIMITED	62%	24: € 49.5 thousand) related to tax assistance. The Audit Committee and the Board of Directors are of the opinion that these non-audit services do not affect the independence of the statutory auditor…
CRL	Charles River Laboratories International, Inc.	62%	Reciprocal relationship from CRL graph: Reciprocal relationship from GLPG graph: 24: € 49.5 thousand) related to tax assistance. The Audit Committee and the Board of Directors are of the opinion that…
GALAPAGOS-GMBH	GALAPAGOS-GMBH	62%	Dr. Paul Stoffels was Chief Executive Officer and Executive Committee member until May 12, 2025, Thad Huston was CFO and Executive Committee member until July 31, 2025, Valeria Cnossen was General Co…
GALAPAGOS-GROUP	GALAPAGOS-GROUP	62%	ended December 31, 2024, and nil for the year ended December 31, 2025. The Belgian and/or French tax authorities may audit each R&D program in respect of which a tax credit has been claimed and asses…
GALAPAGOS-U-K-LIMITED	GALAPAGOS-U-K-LIMITED	62%	Dr. Paul Stoffels was Chief Executive Officer and Executive Committee member until May 12, 2025, Thad Huston was CFO and Executive Committee member until July 31, 2025, Valeria Cnossen was General Co…
GILEAD-BIOPHARMACEUTICS-IRELAND-UNLIMITED-COMPAN	GILEAD-BIOPHARMACEUTICS-IRELAND-UNLIMITED-COMPAN	62%	24: € 49.5 thousand) related to tax assistance. The Audit Committee and the Board of Directors are of the opinion that these non-audit services do not affect the independence of the statutory auditor…
GILEAD-THERAPEUTICS-A1-UNLIMITED-COMPANY	GILEAD-THERAPEUTICS-A1-UNLIMITED-COMPANY	62%	24: € 49.5 thousand) related to tax assistance. The Audit Committee and the Board of Directors are of the opinion that these non-audit services do not affect the independence of the statutory auditor…
GLPG-US-HOLDING-INC	GLPG-US-HOLDING-INC	62%	Dr. Paul Stoffels was Chief Executive Officer and Executive Committee member until May 12, 2025, Thad Huston was CFO and Executive Committee member until July 31, 2025, Valeria Cnossen was General Co…
GLPG-US-INC	GLPG-US-INC	62%	Dr. Paul Stoffels was Chief Executive Officer and Executive Committee member until May 12, 2025, Thad Huston was CFO and Executive Committee member until July 31, 2025, Valeria Cnossen was General Co…
LAKEFRONT-BIOTHERAPEUTICS-INC	LAKEFRONT-BIOTHERAPEUTICS-INC	62%	Dr. Paul Stoffels was Chief Executive Officer and Executive Committee member until May 12, 2025, Thad Huston was CFO and Executive Committee member until July 31, 2025, Valeria Cnossen was General Co…

Lakefront Biotherapeutics NV Debt Obligations

Instrument	Description	Confidence	Evidence
GLPG-DEBT	Debt stack $7.5M	90%	Market cache reports total debt of $7.5M.

Lakefront Biotherapeutics NV Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Lakefront Biotherapeutics NV.

Lakefront Biotherapeutics NV Ownership

Holder	Name	Confidence	Evidence
GLPG-OWNER-GILEAD-SCIENCES-INC	GILEAD SCIENCES, INC.	90%	13F overlay lists GILEAD SCIENCES, INC. as top holder; 92 tracked holders.

Lakefront Biotherapeutics NV Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
PYXS	Pyxis Oncology, Inc.	100.00	2
KYTX	Kyverna Therapeutics, Inc.	100.00	2
ASMB	Assembly Biosciences, Inc.	100.00	2
AVIR	Atea Pharmaceuticals, Inc.	100.00	2
RCUS	Arcus Biosciences, Inc.	100.00	2
KYMR	Kymera Therapeutics, Inc.	100.00	2
TNGX	Tango Therapeutics, Inc.	100.00	2
MGNX	MacroGenics, Inc.	100.00	2
CABA	Cabaletta Bio, Inc.	100.00	2
CAH	Cardinal Health, Inc.	100.00	2
CRL	Charles River Laboratories International, Inc.	100.00	1	['customer']
CRIS	Curis, Inc.	100.00	2
VEEV	Veeva Systems Inc.	100.00	2
GLMD	Galmed Pharmaceuticals Ltd.	100.00	2
SDGR	Schrödinger, Inc.	100.00	2
GDTC	CytoMed Therapeutics Limited	100.00	2
CHRS	Coherus Oncology, Inc.	100.00	2
NRIX	Nurix Therapeutics, Inc.	100.00	2
IBIO	iBio, Inc.	100.00	2
MCK	McKesson Corporation	100.00	2

Lakefront Biotherapeutics NV Supply Chain